Biotech & Pharma

Tamarind Bio Secures $13.6M Series A to Make AI More Accessible for Biology

24 sec read51 views0 listens

Tamarind Bio secured a $13.6 million Series A funding to develop an AI platform making advanced biological research tools accessible without requiring programming expertise. This matters as it addresses the gap between computational and wet lab scientists, enabling broader adoption of AI in life sciences by managing complex infrastructure needs for biotech companies.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Legal & Policy1 day ago32 sec read

A Tribute, A Tactic, Or An Appellate Issue?

A prosecutor's use of hair bows in the Lindsay Clancy murder trial is being scrutinized as a potential tactic that could lead to an appeal, rather than relying solely on evidence. Separately, private equity firm Charlesbank Capital Partners is report...

Ali Nemati

Cybersecurity1 day ago27 sec read

Canadian supercomputers are transforming drug discovery: Can they deliver medicines faster?

Researchers at Simon Fraser University have developed an AI framework called CGFlow, which accelerates the design of drug molecules by ensuring they can be synthesized in a laboratory. This advancement is crucial for reducing the time and cost associ...

Ali Nemati

Biotech & Pharma1 day ago24 sec read

Centrix and University of Sussex Collaborate to Drive Data-Driven Pharma Development

Centrix Pharma Solutions and the University of Sussex have launched a Knowledge Transfer Partnership funded by Innovate UK to develop data-driven tools for pharmaceutical product development. This collaboration aims to integrate advanced analytics wi...

Ali Nemati